TRBC2 and T-cell non-Hodgkin lymphoma: Because about half of TCR+ T-cell lymphomas solely express TRBC1, and normal T cells express only one or the other, using a TRBC1-directed CAR could specifically eliminate malignant cells in patients with TCR+ disease while sparing normal T cells expressing TRBC2 (27, 28).